



US007172874B2

(12) **United States Patent**  
**Hollyfield et al.**

(10) **Patent No.:** **US 7,172,874 B2**  
(45) **Date of Patent:** **Feb. 6, 2007**

(54) **DIAGNOSTIC METHODS FOR AGE RELATED MACULAR DEGENERATION**

(75) Inventors: **Joe G. Hollyfield**, Beachwood, OH (US); **Robert G. Salomon**, Cleveland, OH (US); **John W. Crabb**, Chagrin Falls, OH (US); **Xiaorong Gu**, Lyndhurst, OH (US)

(73) Assignees: **The Cleveland Clinic Foundation**, Cleveland, OH (US); **Case Western Reserve University**, Cleveland, OH (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 582 days.

(21) Appl. No.: **10/135,196**

(22) Filed: **Apr. 30, 2002**

(65) **Prior Publication Data**  
US 2004/0265924 A1 Dec. 30, 2004

**Related U.S. Application Data**  
(60) Provisional application No. 60/287,543, filed on Apr. 30, 2001.

(51) **Int. Cl.**  
**G01N 33/53** (2006.01)  
(52) **U.S. Cl.** ..... **435/7.1**; 435/7.2; 435/7.92; 436/512; 436/513; 436/514; 436/536  
(58) **Field of Classification Search** ..... 435/7.1, 435/7.2, 7.92; 436/512, 513, 514, 536  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,686,250 A 11/1997 Salomon

OTHER PUBLICATIONS

Lecomte et al. J. Neurochemistry 1996 vol. 66, p. 2160.\*  
Bernoud-Hubac et al. J. Biological Chem 2001 vol. 276, p. 30964.\*  
Abstract 2109-B3555, "Oxidative Protein Modification in AMD from Docosahexaenoic Acid" by Crabb, et al., *Investigative Ophthalmology and Visual Science*, vol. 41, No. 4, Mar. 15, 2000.

\* cited by examiner

*Primary Examiner*—Long V. Le

*Assistant Examiner*—Jacob Cheu

(74) *Attorney, Agent, or Firm*—Calfee, Halter & Griswold LLP

(57) **ABSTRACT**

Diagnostic methods for identifying a test subject who has or is at risk of developing age-related macular degeneration (AMD) or an analogous disease associated with oxidation of DHA-containing lipids are provided. In one aspect, the methods comprise: assaying for the presence of elevated levels of 2-( $\omega$ -carboxyethyl) pyrrole (CEP) adducts in a bodily fluid which has been obtained from the test subject. In a preferred embodiment, such methods comprise providing an antibody that is immunospecific for CEP, contacting a bodily fluid from the subject with the anti-CEP antibody, and assaying for the formation of a complex between the antibody and an antigen in the sample. In another aspect, the methods comprise assaying for the presence of elevated levels of an antibody that binds to or is immunospecific for a CEP adduct in the bodily fluid of the test subject. The present invention also relates to CEP protein and peptide adducts, an antibody reactive with a CEP adduct and a diagnostic kit comprising such antibody.

**14 Claims, 7 Drawing Sheets**